blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4339296

EP4339296 - METHOD FOR ASSESSING THE ACTIVITY OF NICOTINAMIDE N-METHYLTRANSFERASE [Right-click to bookmark this link]
StatusThe application has been published
Status updated on  16.02.2024
Database last updated on 25.05.2024
Most recent event   Tooltip16.02.2024Publication in section I.1 EP Bulletinpublished on 20.03.2024  [2024/12]
Applicant(s)For all designated states
Fundación para la Investigación Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana
Avenida Fernando Martorell, 106
Torre A, Planta 7ª
46026 Valencia / ES
For all designated states
Universitat de València
Avda. Blasco Ibáñez, 13
46010 Valencia / ES
For all designated states
Instituto de Investigación Sanitaria INCLIVA
Avda. Menéndez Pelayo 4 acc.
46010 Valencia / ES
[2024/12]
Inventor(s)01 / LAHOZ RODRÍGUEZ, Agustín
46026 Valencia / ES
02 / GARCÍA CAÑAVERAS, Juan Carlos
46026 Valencia / ES
03 / JUAN VIDAL, Oscar
46026 Valencia / ES
04 / HERVÁS, David
46026 Valencia / ES
05 / CARRETERO ASUNCIÓN, Julián
46010 Valencia / ES
06 / PULIDO ENDRINO, Inés
46010 Valencia / ES
07 / MENA MOLLA, Salvador
46010 Valencia / ES
08 / INSA MOLLÁ, Amelia
46010 Valencia / ES
09 / MARTÍN MARTORELL, Paloma
46010 Valencia / ES
 [2024/12]
Representative(s)Hoffmann Eitle
Hoffmann Eitle S.L.U.
Paseo de la Castellana 140, 3a planta
Edificio LIMA
28046 Madrid / ES
[2024/12]
Application number, filing date22382866.619.09.2022
[2024/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4339296
Date:20.03.2024
Language:EN
[2024/12]
Search report(s)(Supplementary) European search report - dispatched on:EP16.03.2023
ClassificationIPC:C12Q1/48, G01N33/50, G01N33/574
[2024/12]
CPC:
C12Q1/48 (EP); G01N33/5011 (EP); G01N33/57423 (EP);
G01N33/57488 (EP); G01N2800/52 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/12]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:VERFAHREN ZUR BEURTEILUNG DER AKTIVITÄT VON NICOTINAMID-N-METHYLTRANSFERASE[2024/12]
English:METHOD FOR ASSESSING THE ACTIVITY OF NICOTINAMIDE N-METHYLTRANSFERASE[2024/12]
French:PROCÉDÉ D'ÉVALUATION DE L'ACTIVITÉ DE NICOTINAMIDE N-MÉTHYLTRANSFÉRASE[2024/12]
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]  - WANG JUN ET AL, "Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells", CELL DEATH DISCOVERY, (20220406), vol. 8, no. 1, doi:10.1038/s41420-022-00966-x, XP093029001 [X] 1,5,11,13,14 * page 6, column 2, paragraph 1 - page 7, column 1, paragraph 1; figures 6,7 * * page 9, column 1, paragraph 2 * * page 9, column 2, paragraph 2 * [I] 2-4,6-8,10,12

DOI:   http://dx.doi.org/10.1038/s41420-022-00966-x
 [A]  - PULIDO I ET AL, "Metabolic vulnerabilities of mesenchymal-like EGFR-mutant NSCLC cells with acquired resistance to tyrosine kinase inhibitors", vol. 78, no. 13, Supplement 1, doi:10.1158/1538-7445.AM2018-LB-099, ISSN 1538-7445, (20180701), pages LB - 099, CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, URL: https://epo.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELYKA2LhLfHWDayGNHEeZWtDW4aUIVRCTJbtuGrU9CFIkfoj-M-cnSA6IKSyZPPjcrbvvrvPZ0JuEHI4LIsEnn5CUtaSLSqzUNERAlzf15JFtoDpa8yG_TDts6RBmr9n8Jt-dGe3ZMiYf9seoLWKaNKh6Nbgqet5LbMV0zj9IXXUpEWT1PdZ6NaMrj_6WbNHa4alt_-PKR2QvdqLhHal9kPS0LMjsjOo8-TH5LM, (20230306), XP009542911 [A] 1-14 * abstract * * paragraph [0003] *

DOI:   http://dx.doi.org/10.1158/1538-7445.AM2018-LB-099
 [XA]  - LI XIAO-YU ET AL, "Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy", FRONTIERS IN ONCOLOGY, CH, (20220609), vol. 12, doi:10.3389/fonc.2022.894744, ISSN 2234-943X, XP093029003 [X] 14 * figures 1,3; table 2 * [A] 1-13

DOI:   http://dx.doi.org/10.3389/fonc.2022.894744
by applicant   - MOTOAKI KOMATSUTAKESHI KANDAHIDENORI URAIARATA KUROKOCHIRINA KITAHAMASHUHEI SHIGAKITAKASHI ONOHIDEO YUKIOKAKAZUHIRO HASEGAWAHIROBUMI TOKUYAMA, "NNMT activation can contribute to the development of fatty liver disease by modulating the NAD + metabolism", Sci Rep, (20180605), vol. 8, no. 1, page 8637
    - HARSHINI NEELAKANTAN et al., "Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle", Biochem Pharmacol, (20190500), vol. 163, doi:10.1016/j.bcp.2019.02.008, pages 481 - 492, XP085659298

DOI:   http://dx.doi.org/10.1016/j.bcp.2019.02.008
    - DANG LWANG Y, "Prognostic value of nicotinamide N-methyltransferase in human cancers: Evidence from a meta-analysis and database validation", Open Med (Wars)., (20220214), vol. 17, no. 1, pages 292 - 303
    - WANG WYANG CWANG TDENG H, "Complex roles of nicotinamide N-methyltransferase in cancer progression", Cell Death Dis, (20220325), vol. 13, no. 3, page 267
    - OGAWA, M.TANAKA, ANAMBA, K. et al., "Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer", Sci Rep, (20220000), vol. 12, page 2767
    - KOCINAJ ACHAUDHURY TUDDIN MS et al., "High Expression of Nicotinamide N-Methyltransferase in Patients with Sporadic Alzheimer's Disease", Mol Neurobiol, (20210000), vol. 58, no. 4, doi:10.1007/s12035-020-02259-9, pages 1769 - 1781, XP037389039

DOI:   http://dx.doi.org/10.1007/s12035-020-02259-9
    - SAMPSON, C.M.DIMET, A.L.NEELAKANTAN, H. et al., "Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice", Sci Rep, (20210000), vol. 11, page 5637
    - DE LAS RIVAS, J., BROZOVIC, A., IZRAELY, S, "Cancer drug resistance induced by EMT: novel therapeutic strategies", Arch Toxicol, vol. 95, doi:10.1007/s00204-021-03063-7, (20210000), pages 2279 - 2297, URL: https://doi.org/10.1007/s00204-021-03063-7, XP037494085

DOI:   http://dx.doi.org/10.1007/s00204-021-03063-7
    - PADHYE, APARNA et al., "''Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.", JCI insight, (20210908), vol. 6, page e148392
    - ESKIOCAK, B.MCMILLAN, E. A.MENDIRATTA, SKOLLIPARA, R. K.ZHANG, H.,HUMPHRIES, C. G.WANG, C.,GARCIA-RODRIGUEZ, J.DING, MZAMAN, A., "Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma", Cancer discovery, vol. 7, no. 8, doi:10.1158/2159-8290.CD-16-0955, (20170000), pages 832 - 851, URL: https://doi.org/10.1158/2159-8290.CD-16-0955, XP055611713

DOI:   http://dx.doi.org/10.1158/2159-8290.CD-16-0955
    - WANG YZENG JWU W et al., "Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization", Breast Cancer Res., (20190517), vol. 21, no. 1, page 64
    - WANG, Y.ZENG, J.WU, W. et al., "Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization", Breast Cancer Res, vol. 21, (20190000), page 64, URL: https://doi.org/10.1186/sl3058-019-1150-z
    - SHLOMI TRABINOWITZ JD, "Metabolism: Cancer mistunes methylation", Nat Chem Biol, (20130000), vol. 9, no. 5, pages 293 - 294
    - YONGZHI GAONATHANIEL I MARTINMATTHIJS J VAN HAREN, "Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target", Drug Discov Today, (20211100), vol. 26, no. ll, pages 2699 - 2706
    - GAO YMARTIN NIVAN HAREN MJ, "Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target", Drug Discov Today, (20210521), vol. 26, no. ll, pages 2699 - 2706
    - KIM DSHAM WSJANG WSCHO KSCHOI YDKANG SKIM BKIM KJLIM EJRHA SY, "Scale-Up Evaluation of a Composite Tumor Marker Assay for the Early Detection of Renal Cell Carcinoma", Diagnostics (Basel, (20200925), vol. 10, no. 10, page 750
    - CAMPAGNA RPOZZI VSPINELLI G et al., "The Utility of Nicotinamide N-Methyltransferase as a Potential Biomarker to Predict the Oncological Outcomes for Urological Cancers: An Update", Biomolecules, (20210816), vol. 11, no. 8, page 1214
    - KANNT, A.RAJAGOPAL, S.KADNUR, S. V. et al., "A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders", Sci Rep, vol. 8, (20180000), page 3660, URL: https://doi.org/10.1038/s41598-018-22081-7
    - MUHAMMAD, N.LEE, H.M.KIM, J, "Oncology Therapeutics Targeting the Metabolism of Amino Acids", Cells, (20200000), vol. 9, page 1904
    - LYNCH, T.J. et al., "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, (20040000), vol. 350, no. 21, doi:10.1056/NEJMoa040938, pages 2129 - 39, XP002447439

DOI:   http://dx.doi.org/10.1056/NEJMoa040938
    - SHEVCHENKO AJENSEN ONPODTELEJNIKOV AVSAGLIOCCO FWILM MVORM OMORTENSEN PBOUCHERIE HMANN M, "Linking genome and proteome by mass spectrometry: large-scale identification of yeast proteins from two dimensional gels", Proceedings of the National Academy of Sciences of the United States of America, (19960000), vol. 93, doi:10.1073/pnas.93.25.14440, pages 14440 - 14445, XP000960780

DOI:   http://dx.doi.org/10.1073/pnas.93.25.14440
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.